Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Alternative Complement Pathway”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Testing effectiveness (Phase 2)Study completedNCT02093533
What this trial is testing

Eculizumab in Primary MPGN

Who this might be right for
Membranoproliferative Glomerulonephritis
Mario Negri Institute for Pharmacological Research 10
Testing effectiveness (Phase 2)Ended earlyNCT03459443
What this trial is testing

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

Who this might be right for
C3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative Glomerulonephritis+2 more
Alexion Pharmaceuticals, Inc. 22
Testing effectiveness (Phase 2)Study completedNCT03439839
What this trial is testing

Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Who this might be right for
Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
Novartis Pharmaceuticals 16
Testing effectiveness (Phase 2)Study completedNCT03369236
What this trial is testing

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

Who this might be right for
C3 GlomerulopathyC3 GlomerulonephritisDense Deposit Disease
Alexion Pharmaceuticals, Inc. 13
Testing effectiveness (Phase 2)Study completedNCT03896152
What this trial is testing

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Who this might be right for
Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals 13
Testing effectiveness (Phase 2)Study completedNCT04330534
What this trial is testing

First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH

Who this might be right for
Paroxysmal Nocturnal Hemoglobinuria
BioCryst Pharmaceuticals 168
Not applicableStudy completedNCT06495151
What this trial is testing

Endometriosis and Complement System

Who this might be right for
EndometriosisComplement SystemAlternative Complement Pathway
Ankara City Hospital Bilkent 58
Not applicableWithdrawnNCT03822195
What this trial is testing

Lectine Pathway in Unstable Carotid Plaque

Who this might be right for
Carotid Artery PlaqueMannose-Binding Lectin Complement Pathway
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Testing effectiveness (Phase 2)Study completedNCT03124368
What this trial is testing

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

Who this might be right for
C3 GlomerulonephritisDense Deposit DiseaseC3 Glomerulopathy+2 more
Alexion Pharmaceuticals, Inc. 6
Testing effectiveness (Phase 2)Ended earlyNCT05097989
What this trial is testing

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Who this might be right for
Lupus NephritisImmunoglobulin A NephropathyIgAN+1 more
Alexion Pharmaceuticals, Inc. 100
Large-scale testing (Phase 3)Active Not RecruitingNCT04557462
What this trial is testing

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Who this might be right for
Primary IgA Nephropathy
Novartis Pharmaceuticals 448
Not applicableLooking for participantsNCT05805202
What this trial is testing

Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy

Who this might be right for
Atypical Hemolytic Uremic Syndrome
Mario Negri Institute for Pharmacological Research 112
Early research (Phase 1)Study completedNCT06100900
What this trial is testing

Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Who this might be right for
Paroxysmal Nocturnal Hemoglobinuria
BioCryst Pharmaceuticals 8
Not applicableNot Yet RecruitingNCT07598448
What this trial is testing

Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain

Who this might be right for
Complement 3 Glomerulopathy
Novartis Pharmaceuticals 35